ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,094.04
-0.15%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Purple Biotech Ltd (PPBT)

  7. Purple Biotech Ltd (PPBT) News

Purple Biotech (PPBT)

Purple Biotech Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PPBT
DateTimeSourceHeadlineSymbolCompany
04/06/202421:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
03/06/202411:21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
01/06/202413:00GlobeNewswire Inc.Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic CancerNASDAQ:PPBTPurple Biotech Ltd
21/05/202412:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
21/05/202412:30GlobeNewswire Inc.Purple Biotech Reports First Quarter 2024 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
25/04/202412:00GlobeNewswire Inc.Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual MeetingNASDAQ:PPBTPurple Biotech Ltd
28/03/202411:00GlobeNewswire Inc.Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024NASDAQ:PPBTPurple Biotech Ltd
14/03/202411:30GlobeNewswire Inc.Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyNASDAQ:PPBTPurple Biotech Ltd
06/03/202421:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
05/03/202421:00Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:PPBTPurple Biotech Ltd
05/03/202412:58Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
05/03/202412:55GlobeNewswire Inc.Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
27/02/202412:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
27/02/202412:00GlobeNewswire Inc.Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024NASDAQ:PPBTPurple Biotech Ltd
13/02/202412:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
13/02/202412:00GlobeNewswire Inc.Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 TrialNASDAQ:PPBTPurple Biotech Ltd
01/02/202412:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
01/02/202412:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
01/02/202412:30GlobeNewswire Inc.Purple Biotech Reaches Recommended Phase 2 Dose for NT219NASDAQ:PPBTPurple Biotech Ltd
26/01/202421:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
20/12/202313:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
20/12/202313:05GlobeNewswire Inc.Purple Biotech Appoints Dr. Yael Margolin to its Board of DirectorsNASDAQ:PPBTPurple Biotech Ltd
14/12/202312:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
14/12/202311:50GlobeNewswire Inc.Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer TrialNASDAQ:PPBTPurple Biotech Ltd
21/11/202312:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
21/11/202311:50GlobeNewswire Inc.Purple Biotech Reports Third Quarter 2023 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
15/11/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PPBTPurple Biotech Ltd
14/11/202321:13Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PPBTPurple Biotech Ltd
13/11/202321:11Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:PPBTPurple Biotech Ltd
02/11/202311:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
 Showing the most relevant articles for your search:NASDAQ:PPBT

Your Recent History

LSE
TLW
Tullow Oil
LSE
SRT
Srt Marine Systems
LSE
GOLD
LSE
SBDS
Silver Bullet Data Servi...
LSE
BIRD
Blackbird
LSE
AV.
Aviva
LSE
LBE
Longboat Energy
LSE
TW.
Taylor Wimpey
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved